Drugs / Candonilimab
Candonilimab
Trials 7 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT06587425 | Jul 2024 → Jul 2025 overdue | adenocarcinoma | Shanghai Zhongshan Hospital | Recruiting | No outcome recorded |
| Phase 2 | NCT06455254 | Jul 2024 → Dec 2025 overdue | — | Jin-hong Chen | Recruiting | No outcome recorded |
| Phase 2 | NCT06487702 | Jul 2024 → Jun 2026 overdue | esophageal squamous cell carcinoma | Rui-hua Xu, MD, PhD | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT05978609 | Jul 2023 → Jul 2025 | cholangiocarcinoma | West China Hospital | Unknown | No outcome recorded |
| Phase 2 | NCT05760599 | Feb 2023 → Jan 2024 | hepatocellular carcinoma | Shi Ming | Unknown | No outcome recorded |
| Phase 2 | NCT05886257 | Dec 2022 → Mar 2023 | hepatocellular carcinoma | Shi Ming | Withdrawn | No outcome recorded |
| Phase 2 | NCT06728631 | Jun 2020 → Dec 2023 overdue | oral cavity cancer, preneoplastic lesion | Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University | Active not recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Candonilimab | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06587425 ↗ |
| Known as | AK104 | “Candonilimab (AK104) is a humanized IgG1 bispecific antibody that targets PD-1 and CTLA-4.” NCT06455254 ↗1“Candonilimab (AK104) is a PD-1/CTLA-4 Bispecific Antibody.” NCT06487702 ↗ |
| Known as | cadonilimab | “cadonilimab (a bispecific antibody targeting PD-1 and CTLA-4)” NCT06587425 ↗ |
| Modality | Monoclonal antibody | “Candonilimab is a humanized bisspecific monoclonal antibody against PD-1/ CTLA-4 IgG1.” NCT05760599 ↗ |
| Route | Intravenous | “iv.drip” NCT05760599 ↗ |